- Home
- ARCT vs HQL Comparison
ARCT vs HQL Comparison
Compare ARCT & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- HQL
- Stock Information
- Founded
- ARCT 2013
- HQL 1992
- Country
- ARCT United States
- HQL United States
- Employees
- ARCT N/A
- HQL N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- HQL Investment Managers
- Sector
- ARCT Health Care
- HQL Finance
- Exchange
- ARCT Nasdaq
- HQL Nasdaq
- Market Cap
- ARCT 444.5M
- HQL 368.7M
- IPO Year
- ARCT N/A
- HQL N/A
- Fundamental
- Price
- ARCT $13.08
- HQL $12.47
- Analyst Decision
- ARCT Strong Buy
- HQL
- Analyst Count
- ARCT 7
- HQL 0
- Target Price
- ARCT $57.80
- HQL N/A
- AVG Volume (30 Days)
- ARCT 451.8K
- HQL 120.9K
- Earning Date
- ARCT 05-07-2025
- HQL 01-01-0001
- Dividend Yield
- ARCT N/A
- HQL 11.56%
- EPS Growth
- ARCT N/A
- HQL N/A
- EPS
- ARCT N/A
- HQL 0.79
- Revenue
- ARCT $152,310,000.00
- HQL N/A
- Revenue This Year
- ARCT N/A
- HQL N/A
- Revenue Next Year
- ARCT $39.21
- HQL N/A
- P/E Ratio
- ARCT N/A
- HQL $17.08
- Revenue Growth
- ARCT N/A
- HQL N/A
- 52 Week Low
- ARCT $8.04
- HQL $11.34
- 52 Week High
- ARCT $45.00
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- ARCT 60.60
- HQL 53.39
- Support Level
- ARCT $10.07
- HQL $11.59
- Resistance Level
- ARCT $11.00
- HQL $11.93
- Average True Range (ATR)
- ARCT 0.89
- HQL 0.40
- MACD
- ARCT 0.53
- HQL 0.12
- Stochastic Oscillator
- ARCT 100.00
- HQL 98.98
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.